Triple Therapy for H. pylori
Standard clarithromycin-based triple therapy (PPI + amoxicillin + clarithromycin) is NO LONGER recommended as first-line empiric treatment for H. pylori in North America due to clarithromycin resistance exceeding 30%. 1
Current First-Line Recommendations
The 2024 ACG guidelines fundamentally changed the approach to H. pylori treatment based on rising antimicrobial resistance patterns 1. Here's what you should prescribe:
Preferred First-Line Regimen
Bismuth quadruple therapy (BQT) for 14 days is the preferred empiric first-line treatment when antibiotic susceptibility is unknown 1:
- Bismuth subsalicylate ~300mg four times daily
- Metronidazole 500mg three times daily
- Tetracycline 500mg four times daily
- PPI (esomeprazole or rabeprazole 20-40mg) twice daily 2, 3
This regimen achieves superior eradication rates compared to traditional triple therapy and remains effective despite metronidazole resistance 3.
Alternative First-Line Options
If BQT is not feasible, two newer alternatives exist 1:
Rifabutin triple therapy for 14 days:
Potassium-competitive acid blocker (vonoprazan) dual therapy for 14 days (where available)
Important caveat: These alternatives should only be used in patients without penicillin allergy 1.
Why Traditional Triple Therapy Fails
The classic PPI-clarithromycin-amoxicillin (PAC) regimen that was standard for decades now achieves only 70-80% eradication rates in intention-to-treat analysis 4, 5. The 2024 guidelines explicitly state clarithromycin resistance now exceeds 30% in North America, making empiric use unacceptable 1.
The only scenario where clarithromycin triple therapy remains appropriate is when antibiotic susceptibility testing confirms clarithromycin susceptibility 2, 1.
Treatment Duration Matters
When triple therapy IS used (based on susceptibility testing), 14-day treatment is superior to 7-day treatment 4, 5. The meta-analysis showed 14-day regimens achieved the highest pooled eradication rates for both clarithromycin and metronidazole-based triple therapies 4.
PPI Selection Is Critical
Not all PPIs are equivalent 3:
- Preferred: Esomeprazole or rabeprazole 20-40mg twice daily (highest potency)
- Avoid: Pantoprazole (significantly lower potency: 40mg pantoprazole = only 9mg omeprazole equivalent)
- Timing: 30 minutes before meals on empty stomach 3
After First-Line Failure
If optimized BQT fails and susceptibility testing is unavailable, rifabutin triple therapy for 14 days is the preferred salvage regimen 2, 1.
After two failed therapies with confirmed adherence, susceptibility testing should be performed to guide subsequent treatment 2. Salvage regimens containing clarithromycin or levofloxacin should only be used with confirmed susceptibility 1.
Common Pitfalls to Avoid
- Do not use clarithromycin-based triple therapy empirically - resistance is too high 1
- Do not use 7-day regimens - 14 days is superior 4, 5
- Do not use concomitant, sequential, or hybrid therapies - these are now considered obsolete as they expose patients to antibiotics that provide no benefit while increasing resistance 3
- Do not substitute doxycycline for tetracycline in BQT - results are significantly inferior 3
Key Takeaway
The landscape has shifted: bismuth quadruple therapy is now the gold standard first-line treatment, not clarithromycin triple therapy. Reserve clarithromycin-containing regimens exclusively for susceptibility-proven cases.